Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervi...(rmaterially from those expressed or impl...),Health

Date:3/31/2008

r materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to: (i) the risk that our APTIMA HPV assay will perform poorly in this clinical trial, (ii) the risk that the APTIMA HPV assay will not be cleared for marketing in the timeframe we expect, if at all, (iii) the possibility that the market for the sale of our APTIMA HPV assay may not develop as expected, (iv) we may not be able to compete effectively with other companies already selling HPV diagnostic products or which launch such products in the future, (v) we depend on a small number of contract manufacturers and single source suppliers of raw materials, (vi) changes in third-party reimbursement policies regarding our products could adversely affect their sales, (vii) changes in government regulation affecting our products could harm our sales and increase our development costs, and (viii) litigation involving the assertion of third party patent rights could be expensive and divert management's attention, and/or result in damages or injunctive relief. The foregoing describes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Contact:

Michael Watts

Senior director, investor relations and

corporate communications

<
'/>"/>

SOURCE Gen-Probe Incorporated Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
2. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
3. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
4. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
5. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
8. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
11. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia